Celestica Inc. (CLS)vsNovo Nordisk A/S (NVO)
CLS
Celestica Inc.
$380.99
+1.45%
TECHNOLOGY · Cap: $43.18B
NVO
Novo Nordisk A/S
$46.40
+0.72%
HEALTHCARE · Cap: $204.22B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 2277% more annual revenue ($327.80B vs $13.79B). NVO leads profitability with a 37.2% profit margin vs 7.0%. CLS appears more attractively valued with a PEG of 1.00. NVO earns a higher WallStSmart Score of 74/100 (B).
CLS
Strong Buy68
out of 100
Grade: B-
NVO
Strong Buy74
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 52 in profit
Revenue surging 52.8% year-over-year
Earnings expanding 147.3% YoY
Growing faster than its price suggests
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 71 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Areas to Watch
7.0% margin — thin
Premium valuation, high expectations priced in
Trading at 20.9x book value
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CLS
The strongest argument for CLS centers on Return on Equity, Revenue Growth, EPS Growth. Revenue growth of 52.8% demonstrates continued momentum. PEG of 1.00 suggests the stock is reasonably priced for its growth.
Bull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bear Case : CLS
The primary concerns for CLS are Profit Margin, P/E Ratio, Price/Book. A P/E of 45.5x leaves little room for execution misses.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
CLS profiles as a hypergrowth stock while NVO is a growth play — different risk/reward profiles.
CLS carries more volatility with a beta of 1.48 — expect wider price swings.
CLS is growing revenue faster at 52.8% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (74/100 vs 68/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Celestica Inc.
TECHNOLOGY · ELECTRONIC COMPONENTS · USA
Celestica Inc. provides hardware platforms and supply chain solutions in North America, Europe, and Asia. The company is headquartered in Toronto, Canada.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other ELECTRONIC COMPONENTS Stocks
Want to dig deeper into these stocks?